"Analysis.group","Analysis.number","Analysis.name","Subgroup","Subgroup.number","Applicability","Study","Study.year","GIV.Mean","GIV.SE","Experimental.mean","Experimental.SD","Experimental.cases","Experimental.N","Control.mean","Control.SD","Control.cases","Control.N","O.E","Variance","Weight","Mean","CI.start","CI.end","Footnotes","Bias.arising.from.the.randomization.process.judgement","Bias.arising.from.the.randomization.process.support","Bias.due.to.deviations.from.intended.interventions.judgement","Bias.due.to.deviations.from.intended.interventions.support","Bias.due.to.missing.outcome.data.judgement","Bias.due.to.missing.outcome.data.support","Bias.in.measurement.of.the.outcome.judgement","Bias.in.measurement.of.the.outcome.support","Bias.in.selection.of.the.reported.result.judgement","Bias.in.selection.of.the.reported.result.support","Overall.bias.judgement","Overall.bias.support","review.url","review.doi","analysis_key","dataset_name","mismatch_type","direction_match","or_sig","rd_sig","log_or","rd","log_or_ci_lb","log_or_ci_ub","rd_ci_lb","rd_ci_ub","sparse_events","double_zero"
1,5,"Proportion of people without histological improvement","",NA,"SUBGROUP_AND_OVERALL","Li 2018",2018,0,1.42275873718717,0,0,4,14,0,0,5,10,0,2.02424242424242,58.021509,0.571429,0.203095,1.607774,"Co-interventions were equally administered to the trial participants in the entecavir and no-treatment/placebo groups.","Some concerns","<p>Quote: ""This is a non-blind, randomized controlled clinical trial; all patients ﻿diagnosed with HBeAg-negative CHB were randomly assigned using a computer-based random number generation program, the program was designed and used by a statistician from Hubei University of Chinese Medicine. ﻿The patients in the three groups showed similar characteristics at baseline (Table 1)"".<br><br>
 Comment: There is no information about how allocation was concealed.&nbsp;</p>","High risk","<p>Quote: ""We have conducted a non-blind, randomized controlled clinical trial"".&nbsp;<br><br>
 Comment: ﻿Blinding was not conducted, there is also no information on whether ﻿deviations from intended interventions that arose because of the trial context. The analysis method was not reported clearly in the full text and was performed based on the participants who completed the treatment and follow-up, which is considered inappropriate.</p>","High risk","<p>Not all patients data were obtained, and the missing rate is high (the total sample size was 130, but 24 did not complete the study; 62 lost at 228 weeks). Sufficient information to permit judgement of high risk of bias.</p>","High risk","<p>Insufficient details on the definition and collection. Open-label trial. This is an observer-decision outcome involving judgement and knowledge of the assigned intervention could influence the outcome measurement.</p>","Some concerns","<p>The study protocol and statistical analysis plan were not available (just mentioned it was reviewed and approved by the Ethics Committee) although this outcome seems to be analyzed and reported in the full text appropriately. No sufficient information to judge whether they were prespecified. Therefore, the judgement for this domain should be some concerns.</p>","High risk","<p>The trial is at high risk of bias in at least one domain for this result in a way that substantially lowers confidence in the result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015536.pub2/full","10.1002/14651858.CD015536.pub2","5::overall","CD015536_pub2_data","significance_only",TRUE,FALSE,TRUE,-1.38020094462444,-0.401465581227486,-2.95352025199125,0.193118362742368,-0.678155397637061,-0.124775764817911,TRUE,TRUE
1,5,"Proportion of people without histological improvement","",NA,"SUBGROUP_AND_OVERALL","Tseng 2014",2014,0,0,0,0,1,21,0,0,10,18,0,0,41.978491,0.085714,0.012112,0.6066,"","Some concerns","<p>Quote: ""﻿This is a prospective randomized, double-blinded, placebo-controlled study...; ﻿Enrolled subjects were allocated according to HBeAg status (HBeAg-positive and HBeAgnegative) and were then randomized to either an entecavir group or placebo group. ﻿The baseline characteristics of the patients in the two groups were similar (Table 1) except for significantly increased total Knodell score, Knodell necroinflammatory score and Knodell fibrosis scores in the placebo compared to the entecavir group"".<br><br>
 Comment: There is no information about how randomisation was performed and how allocation was concealed. Patients baseline imbalance in the total Knodell score was observed between groups, but the difference may not lead to a risk of bias. Therefore, this domain is judged as ‘some concerns’.</p>","Some concerns","<p>Quote: ""﻿This is a prospective randomized, double-blinded, placebo-controlled study"".&nbsp;<br><br>
 Comment: ﻿Double-blinded was performed, but it is difficult to know who was blinded. No information on whether ﻿deviations from intended interventions that arose because of the trial context. Appropriate analysis was used to ﻿estimate the effect of intervention.</p>","Low risk","<p>Almost all ﻿outcome data of included patients were obtained (3/43 withdrew from the clinical trial). Sufficient information to permit judgement of low risk of bias.</p>","Low risk","<p>The measurement and collection were reported in the full text. This is an observer-decision outcome involving judgement, but the outcome was evaluated by a pathologist who was unaware of the treatment.</p>","Some concerns","<p>The study protocol and statistical analysis plan were not available, although it was registered and this outcome seems to be appropriately analyzed and reported in the full text. No sufficient information to judge whether they were prespecified. Therefore, the judgement for this domain should be some concerns.</p>","Some concerns","<p>The trial is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015536.pub2/full","10.1002/14651858.CD015536.pub2","5::overall","CD015536_pub2_data","significance_only",TRUE,FALSE,TRUE,-1.38020094462444,-0.401465581227486,-2.95352025199125,0.193118362742368,-0.678155397637061,-0.124775764817911,TRUE,TRUE
2,4,"Proportion of people with serious adverse events (co-interventions)","Without co-interventions",2,"SUBGROUP_AND_OVERALL","De Man 2001",2001,0,1.42903311442935,0,0,5,34,0,0,0,8,0,2.04213564213564,23.348558,2.828571,0.171859,46.554572,"","Low risk","<p>Quote: ""﻿We conducted a randomized, placebo-controlled, dose-escalating study...; patients were randomly assigned to a dose of entecavir or placebo (8:2). Blinded randomization was performed using a predetermined schedule maintained by the sponsor; bottle assignments were communicated by phone to the individual investigator. ﻿Baseline characteristics are shown in Table 1. All entecavir groups and the placebo group were comparable with regard to sex and age"".<br><br>
 Comment: Sufficient information to permit judgement of low risk of bias.</p>","Some concerns","<p>Quote: ""﻿We conducted a double-blind, placebo-controlled dose-escalating study of 4 dosages of entecavir (0.05 mg, 0.1 mg, 0.5 mg, and 1.0 mg) once daily"".&nbsp;<br><br>
 Comment: ﻿Double-blinded was performed, but it is difficult to know who was blinded. No information on whether ﻿deviations from intended interventions that arose because of the trial context. Appropriate analysis was used to ﻿estimate the effect of intervention.</p>","Low risk","<p>Almost all ﻿outcome data of included patients were obtained (3/42 withdrawn from therapy/discontinuations from treatment). Sufficient information to permit judgement of low risk of bias.</p>","High risk","<p>Insufficient details on the definition and collection. This is participant-reported outcome and the outcome assessor is the study participant. No information on the blinding of patients. Knowledge of the assigned intervention could influence the outcome measurement.</p>","Some concerns","<p>The study protocol and statistical analysis plan were not available (just mentioned the protocol was approved by the Medical Ethics Committee of each participating center with no references) although this outcome seems to be analyzed and reported in the full text appropriately. No sufficient information to judge whether they were prespecified. Therefore, the judgement for this domain should be some concerns.</p>","High risk","<p>The trial is at high risk of bias in at least one domain for this result in a way that substantially lowers confidence in the result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015536.pub2/full","10.1002/14651858.CD015536.pub2","4::2","CD015536_pub2_data","direction_and_significance",FALSE,TRUE,FALSE,-1.02871166838152,0.00326950335187534,-2.05313850636379,-0.00428483039925998,-0.126123813591953,0.132662820295704,TRUE,TRUE
2,4,"Proportion of people with serious adverse events (co-interventions)","Without co-interventions",2,"SUBGROUP_AND_OVERALL","Erken 2021",2021,0,0,0,0,0,7,0,0,0,8,0,0,NA,NA,NA,NA,"","Some concerns","<p>Quote: ""This is a phase Ib, multicentric (Australia, the Netherlands, Poland and Thailand), randomized, doubleblind (Vonefexor or placebo. Entecavir and peg-IFN were not blinded), placebo-controlled, sequential two-part trial. patients were randomly assigned using a block randomization algorithm. ﻿Overall, male and female patients were evenly distributed the mean age of patients was 39.7 years (range, 19–63 years) (Table 1)"".&nbsp;<br><br>
 Comment: There is no information on how allocation was concealed and on the difference of baseline characteristics. But the trial is small in sample size and the difference may not lead to a risk of bias. Therefore, this domain is judged as ‘some concerns’.</p>","Some concerns","<p>Quote: ""A phase Ib, multicentric (Australia, the Netherlands, Poland and Thailand), randomized, doubleblind (Vonefexor or placebo. Entecavir and peg-IFN were not blinded), placebo-controlled, sequential two-part trial was conducted..."".<br><br>
 Comment: ﻿Double-blinded was performed, but it is difficult to know who was blinded. No information on whether ﻿deviations from intended interventions that arose because of the trial context. Appropriate analysis was used to ﻿estimate the effect of intervention.</p>","Low risk","<p>All ﻿data of included patients were obtained. Sufficient information to permit judgement of low risk of bias.</p>","High risk","<p>Insufficient details on the definition and collection. This is participant-reported outcome and the outcome assessor is the study participant. The intervention of entecavir is not blinded for patients and knowledge of the assigned intervention could influence the outcome measurement.</p>","Some concerns","<p>The study protocol was not available (only mentioned in the article but no details provided) although this outcome seems to be analyzed and reported in the full text appropriately. No sufficient information to judge whether they were prespecified. Therefore, the judgement for this domain should be some concerns.</p>","High risk","<p>The trial is judged at high risk of bias in at least one domain for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015536.pub2/full","10.1002/14651858.CD015536.pub2","4::2","CD015536_pub2_data","direction_and_significance",FALSE,TRUE,FALSE,-1.02871166838152,0.00326950335187534,-2.05313850636379,-0.00428483039925998,-0.126123813591953,0.132662820295704,TRUE,TRUE
2,4,"Proportion of people with serious adverse events (co-interventions)","Without co-interventions",2,"SUBGROUP_AND_OVERALL","Jonas 2016",2016,0,0.606512277581537,0,0,4,120,0,0,7,60,0,0.367857142857143,57.294051,0.285714,0.08703,0.937986,"","Low risk","<p>Quote: ""AI463-189 (ClinicalTrials.gov: NCT01079806) is a randomized, double-blind, multicenter, phase III study; Randomization (2:1) was stratified by age group ...and was performed by a sponsor-designated center by an Interactive Voice Response System (IVRS) using a block size of 6. Demographic features and baseline HBV disease characteristics for the overall cohort are shown in Table 1 and Supporting Table 1. At baseline, age distribution was consistent across the entecavir and placebo groups, with a mean age of 10.6 years, and a majority (52%) of children enrolled in the &gt;12- to &lt;18-year-old cohort. Mean HBV-DNA levels were consistent across both groups"".<br><br>
 Comment: Sufficient information to permit judgement of low risk of bias.</p>","Low risk","<p>Quote: ""AI463-189 (ClinicalTrials.gov: NCT01079806) is a randomized, double-blind, multicenter, phase III study; ﻿Blinded treatment was administered for a minimum of 48 weeks; Patients who achieved HBeAg seroconversion at week 48 continued blinded therapy"".<br>
 &nbsp;</p>
<p>Comment: ﻿The trial is double-blinded for the subjects and investigator..&nbsp;</p>","Low risk","<p>Almost all outcome data of included patients were obtained (13/180 discontinuations from treatment). Sufficient information to permit judgement of low risk of bias.</p>","Low risk","<p>Sufficient details on the definition and collection of serious adverse events in the trial protocol. This is participant-reported outcome and the outcome assessor is the study participant. The trial is blinded to patients.</p>","Low risk","<p>Based on the study protocol (protocol was available and published in NCT) and full-text, this outcome was analyzed and reported in the full text as pre-specified. Sufficient information to permit judgement of low risk of bias.</p>","Low risk","<p>The trial is judged at low risk of bias for all domains for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015536.pub2/full","10.1002/14651858.CD015536.pub2","4::2","CD015536_pub2_data","direction_and_significance",FALSE,TRUE,FALSE,-1.02871166838152,0.00326950335187534,-2.05313850636379,-0.00428483039925998,-0.126123813591953,0.132662820295704,TRUE,TRUE
2,4,"Proportion of people with serious adverse events (co-interventions)","Without co-interventions",2,"SUBGROUP_AND_OVERALL","Yao 2005",2005,0,0,0,0,0,141,0,0,0,71,0,0,NA,NA,NA,NA,"","Some concerns","<p>Quote: ""This is a simple, multicenter, randomized, double-blinded trial; There was no significant difference in demographic and clinical characteristics among the groups"". (Translated from Chinese)<br><br>
 Comment: There is no information about how randomisation was performed and how allocation was concealed. Therefore, the judgement for this domain should be some concerns.</p>","Some concerns","<p>Quote: ""This is a simple, multicenter, randomized, double-blinded trial"". (Translated from Chinese)<br><br>
 Comment: Double-blinded was performed, but it is difficult to know who was blinded. No information on whether ﻿deviations from intended interventions that arose because of the trial context. Appropriate analysis was used to ﻿estimate the effect of intervention.</p>","Low risk","<p>All ﻿data of included patients were obtained. Sufficient information to permit judgement of low risk of bias.</p>","High risk","<p>Insufficient details were provided on the definition and collection. This is participant-reported outcome and the outcome assessor is the study participant. No information on the blinding of patients. Knowledge of the assigned intervention could influence the outcome measurement.</p>","Some concerns","<p>The study protocol and statistical analysis plan were not available although this outcome seems to be analyzed and reported in the full text appropriately. No sufficient information to judge whether they were prespecified. Therefore, the judgement for this domain should be some concerns.</p>","High risk","<p>The trial is at high risk of bias in at least one domain for this result in a way that substantially lowers confidence in the result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015536.pub2/full","10.1002/14651858.CD015536.pub2","4::2","CD015536_pub2_data","direction_and_significance",FALSE,TRUE,FALSE,-1.02871166838152,0.00326950335187534,-2.05313850636379,-0.00428483039925998,-0.126123813591953,0.132662820295704,TRUE,TRUE
2,4,"Proportion of people with serious adverse events (co-interventions)","Without co-interventions",2,"SUBGROUP_AND_OVERALL","Yao 2007",2007,0,1.62011923165745,0,0,0,116,0,0,1,29,0,2.62478632478632,19.357391,0.08547,0.003571,2.045795,"","Some concerns","<p>Quote: ""﻿This randomized (4:1), double-blind, placebo-controlled study was conducted at five investigative sites in China. Patients were randomized (4:1) to receive oral entecavir 1 mg daily or placebo for 12 weeks (Fig. 1); ﻿Demographic and pretreatment baseline characteristics were comparable between the two treatment arms (Table 1)"".&nbsp;<br><br>
 Comment: There is no information about how randomisation was performed and how allocation was concealed. Therefore, the judgement for this domain should be some concerns.</p>","Some concerns","<p>Quote: ""This randomized (4:1), double-blind, placebo-controlled study was conducted at five investigative sites in China. All patients completing 12 weeks of blinded treatment..."".<br><br>
 Comment: ﻿The trial is double-blinded, but only reported the blinding for patients and it is difficult to know another blinded party. No information on whether ﻿deviations from intended interventions that arose because of the trial context. Appropriate analysis was used to ﻿estimate the effect of intervention.</p>","Low risk","<p>Almost all ﻿outcome data of included patients were obtained (1/147 patient discontinued blinded treatment at week 10 owing to adverse events). Sufficient information to permit judgement of low risk of bias.</p>","Some concerns","<p>Insufficient details were provided on the definition and collection. This is participant-reported outcome and the outcome assessor is the study participant. The trial is blinded to patients.</p>","Some concerns","<p>The study protocol and statistical analysis plan were not available although this outcome seems to be analyzed and reported in the full text appropriately. No sufficient information to judge whether they were prespecified. Therefore, the judgement for this domain should be some concerns.</p>","Some concerns","<p>The trial is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015536.pub2/full","10.1002/14651858.CD015536.pub2","4::2","CD015536_pub2_data","direction_and_significance",FALSE,TRUE,FALSE,-1.02871166838152,0.00326950335187534,-2.05313850636379,-0.00428483039925998,-0.126123813591953,0.132662820295704,TRUE,TRUE
3,5,"Proportion of people with serious adverse events (restricting the analysis to no industry-funded trials)","",NA,"SUBGROUP_AND_OVERALL","Li 2018",2018,0,0,0,0,0,23,0,0,0,26,0,0,NA,NA,NA,NA,"Co-interventions were equally administered to the trial participants in the entecavir and no-treatment/placebo groups.","Some concerns","<p>Quote: ""This is a non-blind, randomized controlled clinical trial; all patients ﻿diagnosed with HBeAg-negative CHB were randomly assigned using a computer-based random number generation program, the program was designed and used by a statistician from Hubei University of Chinese Medicine. ﻿The patients in the three groups showed similar characteristics at baseline (Table 1)"".<br><br>
 Comment: There is no information about how allocation was concealed.&nbsp;</p>","High risk","<p>Quote: ""We have conducted a non-blind, randomized controlled clinical trial"".&nbsp;<br><br>
 Comment: ﻿Blinding was not conducted, there is also no information on whether ﻿deviations from intended interventions that arose because of the trial context. The analysis method was not reported clearly in the full text and was performed based on the participants who completed the treatment and follow-up, which is considered inappropriate.</p>","High risk","<p>Comment: Not all patients data were obtained, and the missing rate is high (the total sample size was 130, but 24 did not complete the study; 62 lost at 228 weeks). Sufficient information to permit judgement of high risk of bias.</p>","High risk","<p>Insufficient details on the definition and collection. This is participant-reported outcome and the outcome assessor is the study participant. The trial is non-blinded and knowledge of the assigned intervention could influence the outcome measurement.</p>","Some concerns","<p>The study protocol and statistical analysis plan were not available (just mentioned it was reviewed and approved by the Ethics Committee) although this outcome seems to be analyzed and reported in the full text appropriately. No sufficient information to judge whether they were prespecified. Therefore, the judgement for this domain should be some concerns.</p>","High risk","<p>The trial is at high risk of bias in at least one domain for this result in a way that substantially lowers confidence in the result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015536.pub2/full","10.1002/14651858.CD015536.pub2","5::overall","CD015536_pub2_data","significance_only",TRUE,FALSE,TRUE,-1.38020094462444,-0.401465581227486,-2.95352025199125,0.193118362742368,-0.678155397637061,-0.124775764817911,TRUE,TRUE
3,5,"Proportion of people with serious adverse events (restricting the analysis to no industry-funded trials)","",NA,"SUBGROUP_AND_OVERALL","Zeng 2013",2013,0,0,0,0,0,20,0,0,0,20,0,0,NA,NA,NA,NA,"Co-interventions were equally administered to the trial participants in the entecavir and no-treatment/placebo groups.","Some concerns","<p>Quote: ""60 HBeAg positive patients were randomly divided into three groups; The disease characteristics of the three groups of patients are shown in Table 1, and the differences are not statistically significant"". (Translated from Chinese)<br><br>
 Comment: There is no information about how randomisation was performed and how allocation was concealed. Therefore, the judgement for this domain should be some concerns.</p>","Some concerns","<p>Quote: “60 HBeAg positive patients were randomly divided into three groups"".&nbsp;<br><br>
 Comment: The authors only reported that patients were randomly selected and divided into a study group and a control group, there is no information on blinding and whether ﻿deviations from intended interventions that arose because of the trial context. Appropriate analysis was used to ﻿estimate the effect of intervention.</p>","Low risk","<p>All ﻿data of included patients were obtained. Sufficient information to permit judgement of low risk of bias.</p>","High risk","<p>Insufficient details on the definition and collection. This is participant-reported outcome and the outcome assessor is the study participant. No information on the blinding of patients. Knowledge of the assigned intervention could influence the outcome measurement.</p>","Some concerns","<p>The study protocol and statistical analysis plan were not available although this outcome seems to be analyzed and reported in the full text appropriately. No sufficient information to judge whether they were prespecified. Therefore, the judgement for this domain should be some concerns.</p>","High risk","<p>The trial is at high risk of bias in at least one domain for this result in a way that substantially lowers confidence in the result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015536.pub2/full","10.1002/14651858.CD015536.pub2","5::overall","CD015536_pub2_data","significance_only",TRUE,FALSE,TRUE,-1.38020094462444,-0.401465581227486,-2.95352025199125,0.193118362742368,-0.678155397637061,-0.124775764817911,TRUE,TRUE
